AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
When the Treatment Exists but the Patient Never Gets It: The 2026 Summit on Cancer Health Disparities
By Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.
When the Treatment Exists but the Patient Never Gets It: The 2026 Summit on Cancer Health Disparities
By Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.
When the Treatment Exists but the Patient Never Gets It: The 2026 Summit on Cancer Health Disparities
By Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Where You Live Matters: How Neighborhood Conditions Shape Cancer Outcomes and Survival Disparities
By Chalothorn Wannaphut, MD
How neighborhood conditions shape cancer outcomes. Explore how social determinants of health influence diagnosis, treatment delays, and survival disparities—and what can be done to improve equity.
Where You Live Matters: How Neighborhood Conditions Shape Cancer Outcomes and Survival Disparities
By Chalothorn Wannaphut, MD
How neighborhood conditions shape cancer outcomes. Explore how social determinants of health influence diagnosis, treatment delays, and survival disparities—and what can be done to improve equity.
Where You Live Matters: How Neighborhood Conditions Shape Cancer Outcomes and Survival Disparities
By Chalothorn Wannaphut, MD
How neighborhood conditions shape cancer outcomes. Explore how social determinants of health influence diagnosis, treatment delays, and survival disparities—and what can be done to improve equity.
Precision Frontiers in Hepatobiliary Oncology: FGFR2 Selectivity and Immunotherapy in HCC and iCCA
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: FGFR2 Selectivity and Immunotherapy in HCC and iCCA
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: FGFR2 Selectivity and Immunotherapy in HCC and iCCA
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
“They Told Me It’s Stage 4.” Does Stage 4 Cancer Always Mean the End?
By Matthew Meranda, DO
A stage 4 cancer diagnosis is serious—but not always terminal. Dr. Matthew Meranda explains what stage 4 means, how metastatic cancer is treated today, and how patients can navigate prognosis and communication with their care team.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancer Treatment
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancer Treatment
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancer Treatment
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. Rachael A. Safyan on Pancreatic Cancer: Evolving Treatment Paradigms from Resectable to Metastatic Disease
By The Cancer News Team
Dr. Rachael A. Safyan reviews evolving treatment strategies in pancreatic cancer, from neoadjuvant therapy and tumor-treating fields to RAS-targeted agents reshaping metastatic care.
Dr. David Zhen on Advances in Neuroendocrine Tumor Treatment, From New Therapies to Radioligands
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen on Advances in Neuroendocrine Tumor Treatment, From New Therapies to Radioligands
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.
Dr. David Zhen on Advances in Neuroendocrine Tumor Treatment, From New Therapies to Radioligands
By The Cancer News Team
Dr. David Zhen reviews major advances in neuroendocrine tumor treatment, including cabozantinib approval, earlier use of PRRT, emerging alpha-emitter radioligand therapies, and novel targeted agents.